Menopause cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
*Hormone replacement therapy is Cost-effective for the relief of menopausal symptoms either was severe or mild. | |||
*HRT not cost-effective for asymptomatic women for prevention of medical diseases associated with postmenopause. | |||
*The Cost-effectiveness of hormone replacement therapy ratios between 10,000 a million $ per QALY (quality-adjusted life expectancy). | |||
*There are several factors that improved cost-effectiveness such as the long duration of therapy, the presence of menopausal symptoms, and minimum side effects of hormonal therapy.<ref name="pmid19857096">{{cite journal| author=Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA| title=Cost-effectiveness of hormone therapy in the United States. | journal=J Womens Health (Larchmt) | year= 2009 | volume= 18 | issue= 10 | pages= 1669-77 | pmid=19857096 | doi=10.1089/jwh.2008.1246 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19857096 }} </ref><ref name="pmid12945798">{{cite journal| author=Burger H| title=Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. | journal=Climacteric | year= 2003 | volume= 6 Suppl 1 | issue= | pages= 11-36 | pmid=12945798 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12945798 }} </ref><ref name="pmid1588862">{{cite journal| author=Cheung AP, Wren BG| title=A cost-effectiveness analysis of hormone replacement therapy in the menopause. | journal=Med J Aust | year= 1992 | volume= 156 | issue= 5 | pages= 312-6 | pmid=1588862 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1588862 }} </ref> | |||
Revision as of 23:21, 1 March 2021
|
Menopause Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Menopause cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Menopause cost-effectiveness of therapy |
|
Risk calculators and risk factors for Menopause cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Rahmah Al-Edresi, M.D.[2]
Overview
Cost-Effectiveness of Therapy
- Hormone replacement therapy is Cost-effective for the relief of menopausal symptoms either was severe or mild.
- HRT not cost-effective for asymptomatic women for prevention of medical diseases associated with postmenopause.
- The Cost-effectiveness of hormone replacement therapy ratios between 10,000 a million $ per QALY (quality-adjusted life expectancy).
- There are several factors that improved cost-effectiveness such as the long duration of therapy, the presence of menopausal symptoms, and minimum side effects of hormonal therapy.[1][2][3]
References
- ↑ Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA (2009). "Cost-effectiveness of hormone therapy in the United States". J Womens Health (Larchmt). 18 (10): 1669–77. doi:10.1089/jwh.2008.1246. PMID 19857096.
- ↑ Burger H (2003). "Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003". Climacteric. 6 Suppl 1: 11–36. PMID 12945798.
- ↑ Cheung AP, Wren BG (1992). "A cost-effectiveness analysis of hormone replacement therapy in the menopause". Med J Aust. 156 (5): 312–6. PMID 1588862.